From PCR for diagnostics of acute cases to serological tests for differentiated detection of antibodies of different immunoglobulin classes against different SARS-CoV-2 antigens – we provide you with the appropriate tools to answer your diagnostic question.
All tests are CE-marked. Moreover, the Anti-SARS-CoV-2 ELISA (IgG) and the EURORealTime SARS-CoV-2 have been approved for use in authorised laboratories by the U.S. Food and Drug Administration (FDA) via an Emergency Use Authorization (EUA)
New ELISA for the detection of IgM antibodies against NCP of SARS-CoV-2 now available
ELISA for detection of IgG antibodies against S1 and NCP of SARS-CoV-2 are now validated for the use of dried capillary blood (dried blood spots – DBS) as an alternative sample material.
EURORealTime SARS-CoV-2 approved by FDA via EUA
Now available: New ELISA format, optimized for automatic processing with the EUROLabWorkstation ELISA
The RT-PCR is the method of choice for diagnostics of acute SARS-CoV-2 infections and allows direct virus detection. The CE-marked EURORealTime SARS-CoV-2 detects two genetic sequences of the virus in parallel and has an analytical sensitivity of 1 cp/µl.
EUROIMMUN offers CE-marked ELISAs for the detection of antibodies against modified nucleocapsid protein (IgM or IgG) as well as the S1 domain of the spike protein (IgA and IgG). In combination with the IgG ELISA, capillary blood (dried blood spots – DBS) can now be also used as alternative sample material. In this way, we offer a comprehensive and highly effective package for serological COVID-19 diagnostics.
The ELISAs are used worldwide by renowned diagnostic laboratories, reference institutes, clinics and research institutions in order to diagnose and investigate COVID-19.
Download flyers and further information material here.
EUROIMMUN develops and produces test systems for doctors and laboratories that cannot be performed by private individuals.